Replies to post #125845 on Biotech Values

[DewDiligence]

No, but good guess. RE-LY (http://www.clinicaltrials.gov/ct2/show/NCT00262600 ) was the only phase-3 trial for Pradaxa in AF. It was blinded with respect to the two doses of Pradaxa, but open-label with respect to the warfarin arm.